0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Immunotech Laboratories
Its shares trade under the ticker IMMB. It has been listed since 7 January 2002.
Immunotech Laboratories, Inc. is a drug development company. The company is headquartered in Monrovia California, California. The company went IPO on 2002-01-07. The firm offers a drug platform, Irreversible Pepsin Fraction (IPF), which is a technology that can be used to facilitate a range of applications. Its flagship compound Immune Therapeutic Vaccine-1 (ITV-1) is a suspension of IPF, which is used in the treatment of human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) and Hepatitis C viruses and to modulate the immune system. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. The IPF modulates helper T1 cells expression of elaborate cytokines interferon (INF)-gamma, interleukin-2 (IL-2), which selectively promotes cell-mediated immune response and subsequently stimulates cytotoxic lymphocytes. The firm's other compounds in its pipeline include ITV-2 prenatal, ITV-3 Pediatric and ITV-4 HIV Vaccine.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 7 Jan 2002
- Employees
- 4
- Website
- immunotechlab.com ↗
Leadership
Pay as last reported
- Mr. Harry ZhabilovVice Chairman of the Board, Chief Science Officer, since 2007
- Dr. Roscoe MooreDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Immunotech Laboratories Inc. excels in its advanced research and development capabilities. The company's scientific expertise enables it to innovate and stay at the forefront of the biotechnology industry, allowing for the development of groundbreaking solutions.
- Immunotech Laboratories Inc. possesses a robust intellectual property portfolio, including patents, trademarks, and proprietary technologies. This portfolio grants the company a competitive advantage, protecting its innovations and offering opportunities for lucrative licensing agreements.
- With a diversified product portfolio, Immunotech Laboratories Inc. mitigates risk and maximizes market opportunities. The company offers a range of biotech products addressing various diseases and conditions, ensuring multiple revenue streams and reducing dependency on a single product line.
Weaknesses
- One of the weaknesses of Immunotech Laboratories Inc. is its reliance on external funding sources for research and development initiatives. This vulnerability exposes the company to potential financial constraints and fluctuations in funding availability.
- Despite its strengths, Immunotech Laboratories Inc. has a relatively small market presence compared to established industry giants. This limited market reach may hinder the company's ability to compete effectively and gain significant market share.
Opportunities
- The growing demand for biotech solutions presents a significant opportunity for Immunotech Laboratories Inc. to expand its customer base and boost revenue. The increasing prevalence of diseases and the need for effective treatments positions the company for potential growth and market penetration.
- Immunotech Laboratories Inc. can leverage collaboration and partnerships with other biotechnology firms, academic institutions, and healthcare organizations. Such alliances provide access to additional resources, expertise, and market networks, enabling the company to accelerate research, development, and commercialization efforts.
Threats
- Immunotech Laboratories Inc. faces fierce competition within the highly competitive biotechnology industry. Rival companies with larger market shares and established customer bases may pose a challenge to the company's growth and market positioning.
- The biotech industry is subject to stringent regulations and compliance requirements. Immunotech Laboratories Inc. must navigate and comply with various regulatory frameworks, which can be complex, time-consuming, and costly. Failure to meet these obligations may result in penalties or restrictions on product development and commercialization activities.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.